Mergers and acquisitions in the pharmaceutical and biotech industries
Article first published online: 17 AUG 2007
Copyright © 2007 John Wiley & Sons, Ltd.
Managerial and Decision Economics
Special Issue: Economic and Policy Issues in the Pharmaceutical Industry
Volume 28, Issue 4-5, pages 307–328, June - August 2007
How to Cite
Danzon, P. M., Epstein, A. and Nicholson, S. (2007), Mergers and acquisitions in the pharmaceutical and biotech industries. Manage. Decis. Econ., 28: 307–328. doi: 10.1002/mde.1343
- Issue published online: 17 AUG 2007
- Article first published online: 17 AUG 2007
- Merck Company Foundation
- Huntsman Center
We examine the determinants and effects of M&A activity in the pharmaceutical/biotechnology industry using SDC data on 383 firms from 1988 to 2001. For large firms, mergers are a response to expected excess capacity due to patent expirations and gaps in a firm's product pipeline. For small firms, mergers are primarily an exit strategy in response to financial trouble (low Tobin's q, few marketed products, low cash–sales ratios). In estimating effects of mergers, we use a propensity score to control for selection based on observed characteristics. Controlling for merger propensity, large firms that merged experienced a similar change in enterprise value, sales, employees, and R&D, and had slower growth in operating profit, compared with similar firms that did not merge. Thus mergers may be a response to trouble, but they are not a solution. Copyright © 2007 John Wiley & Sons, Ltd.